期刊文献+

Molecular biology of pancreatic cancer 被引量:7

Molecular biology of pancreatic cancer
下载PDF
导出
摘要 In spite of continuous research efforts directed at early detection and treatment of pancreatic cancer, the outlook for patients affected by the disease remains dismal. With most cases still being diagnosed at advanced stages, no improvement in survival prognosis is achieved with current diagnostic imaging approaches. In the absence of a dominant precancerous condition, several risk factors have been identified including family history, chronic pancreatitis, smoking, diabetes mellitus, as well as certain genetic disorders such as hereditary pancreatitis, cystic fibrosis, familial atypical multiple mole melanoma, and Peutz-Jeghers and Lynch syn- dromes. Most pancreatic carcinomas, however, remain sporadic. Current progress in experimental molecular techniques has enabled detailed understanding of the molecular processes of pancreatic cancer development. According to the latest information, malignant pancre- atic transformation involves multiple oncogenes and tumor-suppressor genes that are involved in a variety of signaling pathways. The most characteristic aberrations (somatic point mutations and allelic losses) affect onco- genes and tumor-suppressor genes within RAS, AK-I- and Wnt signaling, and have a key role in transcription and proliferation, as well as systems that regulate the cell cycle (SMAD/DPC, CDKN2A/p16) and apoptosis (TP53). Understanding of the underlying molecular mechanisms should promote development of new methodology for early diagnosis and facilitate improvement in current approaches for pancreatic cancer treatment. In spite of continuous research efforts directed at early detection and treatment of pancreatic cancer, the outlook for patients affected by the disease remainsdismal. With most cases still being diagnosed at ad- vanced stages, no improvement in survival prognosis is achieved with current diagnostic imaging approaches. In the absence of a dominant precancerous condition, several risk factors have been identified including family history, chronic pancreatitis, smoking, diabetes mellitus, as well as certain genetic disorders such as hereditary pancreatitis, cystic fibrosis, familial atypical multiple mole melanoma, and Peutz-Jeghers and Lynch syn- dromes. Most pancreatic carcinomas, however, remain sporadic. Current progress in experimental molecular techniques has enabled detailed understanding of the molecular processes of pancreatic cancer development. According to the latest information, malignant pancre- atic transformation involves multiple oncogenes and tumor-suppressor genes that are involved in a variety of signaling pathways. The most characteristic aberrations (somatic point mutations and allelic losses) affect onco- genes and tumor-suppressor genes within RAS, AKT and Wnt signaling, and have a key role in transcription and proliferation, as well as systems that regulate the cell cycle (SMAD/DPC, CDKN2A/p16) and apoptosis (TP53). Understanding of the underlying molecular mechanisms should promote development of new methodology for early diagnosis and facilitate improvement in current ap- proaches for pancreatic cancer treatment.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第24期2897-2908,共12页 世界胃肠病学杂志(英文版)
关键词 Pancreatic cancer Risk factors Molecularbiology PANCREATITIS DIABETES 分子生物学技术 胰腺癌 遗传性疾病 抑癌基因 诊断方法 信号通路 早期诊断 风险因素
  • 相关文献

参考文献2

二级参考文献32

  • 1[1]Jemal A,Murray T,Ward E,Samuels A,Tiwari RC,Ghafoor A,Feuer EJ,Thun MJ.Cancer statistics,2005.CA Cancer J Clin 2005; 55:10-30
  • 2[2]Yamamoto M,Ohashi O,Saitoh Y.Japan Pancreatic Cancer Registry:current status.Pancreas 1998; 16:238-242
  • 3[3]Matsuno S,Egawa S,Fukuyama S,Motoi F,Sunamura M,Isaji S,Imaizumi T,Okada S,Kato H,Suda K,Nakao A,Hiraoka T,Hosotani R,Takeda K.Pancreatic Cancer Registry in Japan:20years of experience.Pancreas 2004; 28:219-230
  • 4[4]Tanaka M.Important clues to the diagnosis of pancreatic cancer.Rocz Akad Med Bialymst 2005; 50:69-72
  • 5[5]Matsumoto K,Nakamura T.Emerging multipotent aspects of hepatocyte growth factor.J Biochem (Tokyo) 1996; 119:591-600
  • 6[6]Giordano S,Di Renzo MF,Narsimhan RP,Cooper CS,Rosa C,Comoglio PM.Biosynthesis of the protein encoded by the c-met proto-oncogene.Oncogene 1989; 4:1383-1388
  • 7[7]Galimi F,Brizzi MF,Comoglio PM.The hepatocyte growth factor and its receptor.Stem Cells 1993; 11 Suppl 2:22-30
  • 8[8]Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF.Met,metastasis,motility and more.Nat Rev Mol Cell Biol 2003; 4:915-925
  • 9[9]Ghoussoub RA,Dillon DA,D'Aquila T,Rimm EB,Fearon ER,Rimm DL.Expression of c-met is a strong independent prognostic factor in breast carcinoma.Cancer 1998; 82:1513-1520
  • 10[10]Kuniyasu H,Yasui W,Yokozaki H,Kitadai Y,Tahara E.Aberrant expression of c-met mRNA in human gastric carcinomas.Int J Cancer 1993; 55:72-75

共引文献20

同被引文献55

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部